{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T12:00:33Z","timestamp":1776427233242,"version":"3.51.2"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,14]],"date-time":"2025-10-14T00:00:00Z","timestamp":1760400000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,10,14]],"date-time":"2025-10-14T00:00:00Z","timestamp":1760400000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Ovarian Res"],"DOI":"10.1186\/s13048-025-01789-x","type":"journal-article","created":{"date-parts":[[2025,10,14]],"date-time":"2025-10-14T12:11:14Z","timestamp":1760443874000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Ovarian reserve and stimulation response before chemotherapy treatment in breast cancer patients undergoing fertility preservation: a historical cohort study"],"prefix":"10.1186","volume":"18","author":[{"given":"Nadia","family":"Jahangiri","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Firouzeh","family":"Ghaffari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maryam","family":"Hafezi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bita","family":"Ebrahimi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samira","family":"Vesali","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Asiie","family":"Olfatbakhsh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sahar","family":"Hosseini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,10,14]]},"reference":[{"key":"1789_CR1","first-page":"394","volume":"68","author":"F Bray","year":"2018","unstructured":"Bray F, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394\u2013424.","journal-title":"CA Cancer J Clin"},{"key":"1789_CR2","first-page":"209","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209\u201349.","journal-title":"CA Cancer J Clin"},{"key":"1789_CR3","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1007\/s10815-023-02739-6","volume":"40","author":"I Sellami","year":"2023","unstructured":"Sellami I, et al. Oocyte vitrification for fertility preservation following COS does not delay the initiation of neoadjuvant chemotherapy for breast cancer compared to IVM. J Assist Reprod Genet. 2023;40:473\u201380.","journal-title":"J Assist Reprod Genet"},{"key":"1789_CR4","doi-asserted-by":"crossref","unstructured":"Anderson RA , et al. ESHRE guideline: female fertility preservation. Hum Reprod Open. 2020; 2020:hoaa052.","DOI":"10.1093\/hropen\/hoaa052"},{"key":"1789_CR5","doi-asserted-by":"publisher","first-page":"1664","DOI":"10.1016\/j.annonc.2020.09.006","volume":"31","author":"M Lambertini","year":"2020","unstructured":"Lambertini M, et al. Fertility preservation and post-treatment pregnancies in post-pubertal cancer patients: ESMO clinical practice guidelines. Ann Oncol. 2020;31:1664\u201378.","journal-title":"Ann Oncol"},{"key":"1789_CR6","doi-asserted-by":"publisher","first-page":"103776","DOI":"10.1016\/j.breast.2024.103776","volume":"77","author":"A Dezellus","year":"2024","unstructured":"Dezellus A, et al. Use of tamoxifene-controlled ovarian hyperstimulation for fertility preservation before breast cancer treatment: A prospective cohort study with a 5-year follow-up. Breast. 2024;77:103776.","journal-title":"Breast"},{"key":"1789_CR7","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1097\/GCO.0000000000000180","volume":"27","author":"H Cakmak","year":"2015","unstructured":"Cakmak H, Rosen MP. Random-start ovarian stimulation in patients with cancer. Curr Opin Obstet Gynecol. 2015;27:215\u201321.","journal-title":"Curr Opin Obstet Gynecol"},{"key":"1789_CR8","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/j.ejogrb.2016.02.006","volume":"199","author":"MV Wolff","year":"2016","unstructured":"Wolff MV, et al. Timing of ovarian stimulation in patients prior to gonadotoxic therapy: an analysis of 684 stimulations. Eur J Obstet Gynecol Reprod Biol. 2016;199:146\u20139.","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"1789_CR9","doi-asserted-by":"publisher","first-page":"242","DOI":"10.5468\/ogs.2018.61.2.242","volume":"61","author":"YJ Shim","year":"2018","unstructured":"Shim YJ, et al. The serum estradiol\/oocyte ratio in patients with breast cancer undergoing ovarian stimulation with letrozole and gonadotropins. Obstet Gynecol Sci. 2018;61:242\u20136.","journal-title":"Obstet Gynecol Sci"},{"key":"1789_CR10","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1080\/09513590.2016.1177013","volume":"32","author":"N Pereira","year":"2016","unstructured":"Pereira N, et al. Comparison of ovarian stimulation response in patients with breast cancer undergoing ovarian stimulation with letrozole and gonadotropins to patients undergoing ovarian stimulation with gonadotropins alone for elective cryopreservation of oocytes. Gynecol Endocrinol. 2016;32:823\u20136.","journal-title":"Gynecol Endocrinol"},{"key":"1789_CR11","first-page":"91","volume":"23","author":"CC de Moraes","year":"2019","unstructured":"de Moraes CC, et al. Oocyte cryopreservation for future fertility: comparison of ovarian response between cancer and non-cancer patients. JBRA Assist Reprod. 2019;23:91.","journal-title":"JBRA Assist Reprod"},{"key":"1789_CR12","doi-asserted-by":"publisher","first-page":"101944","DOI":"10.1016\/j.jogoh.2020.101944","volume":"50","author":"RS Hussein","year":"2021","unstructured":"Hussein RS, et al. Does type of cancer affect ovarian response in oncofertility patients? J Gynecol Obstet Hum Reprod. 2021;50:101944.","journal-title":"J Gynecol Obstet Hum Reprod"},{"key":"1789_CR13","first-page":"407","volume":"26","author":"ATF Kira","year":"2022","unstructured":"Kira ATF, et al. Patients undergoing elective and oncofertility preservation respond similarly to controlled ovarian stimulation for fertility preservation. JBRA Assist Reprod. 2022;26:407.","journal-title":"JBRA Assist Reprod"},{"key":"1789_CR14","doi-asserted-by":"publisher","first-page":"104109","DOI":"10.1016\/j.rbmo.2024.104109","volume":"49","author":"M Grynberg","year":"2024","unstructured":"Grynberg M, et al. Effect of breast cancer prognostic factors on ovarian reserve and response in fertility preservation. Reprod Biomed Online. 2024;49:104109.","journal-title":"Reprod Biomed Online"},{"key":"1789_CR15","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1016\/j.fertnstert.2012.01.093","volume":"97","author":"J Domingo","year":"2012","unstructured":"Domingo J, et al. Ovarian response to controlled ovarian hyperstimulation in cancer patients is diminished even before oncological treatment. Fertil Steril. 2012;97:930\u20134.","journal-title":"Fertil Steril"},{"key":"1789_CR16","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.fertnstert.2011.10.014","volume":"97","author":"S Friedler","year":"2012","unstructured":"Friedler S, et al. Ovarian response to stimulation for fertility preservation in women with malignant disease: a systematic review and meta-analysis. Fertil Steril. 2012;97:125\u201333.","journal-title":"Fertil Steril"},{"key":"1789_CR17","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/j.rbmo.2019.11.006","volume":"40","author":"A Volodarsky-Perel","year":"2020","unstructured":"Volodarsky-Perel A, et al. Influence of stage and grade of breast cancer on fertility preservation outcome in reproductive-aged women. Reprod Biomed Online. 2020;40:215\u201322.","journal-title":"Reprod Biomed Online"},{"key":"1789_CR18","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/j.fertnstert.2009.03.028","volume":"94","author":"SC Klock","year":"2010","unstructured":"Klock SC, Zhang JX, Kazer RR. Fertility preservation for female cancer patients: early clinical experience. Fertil Steril. 2010;94:149\u201355.","journal-title":"Fertil Steril"},{"key":"1789_CR19","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.fertnstert.2012.04.021","volume":"98","author":"B Lawrenz","year":"2012","unstructured":"Lawrenz B, et al. Reduced pretreatment ovarian reserve in premenopausal female patients with hodgkin lymphoma or non-Hodgkin-lymphoma\u2013evaluation by using antimullerian hormone and retrieved oocytes. Fertil Steril. 2012;98:141\u20134.","journal-title":"Fertil Steril"},{"key":"1789_CR20","doi-asserted-by":"crossref","unstructured":"Wu M et al. Ovarian reserve in reproductive-aged patients with cancer before gonadotoxic treatment: A systematic review and meta-analysis. Hum Reprod Open.2023; 2023:hoad024.","DOI":"10.1093\/hropen\/hoad024"},{"key":"1789_CR21","doi-asserted-by":"publisher","first-page":"1616","DOI":"10.1093\/humrep\/der092","volume":"26","author":"A Ferraretti","year":"2011","unstructured":"Ferraretti A, et al. ESHRE consensus on the definition of \u2018poor response\u2019to ovarian stimulation for in vitro fertilization: the Bologna criteria. Hum Reprod. 2011;26:1616\u201324.","journal-title":"Hum Reprod"},{"key":"1789_CR22","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.fertnstert.2003.10.004","volume":"81","author":"ESHRE Rotterdam","year":"2004","unstructured":"Rotterdam ESHRE, ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril. 2004;81:19\u201325.","journal-title":"Fertil Steril"},{"key":"1789_CR23","first-page":"293","volume":"18","author":"EM Meighani","year":"2024","unstructured":"Meighani EM, et al. Fertility preservation in female patients with cancer. Part I: challenges and future prospects in developing countries; a narrative review study. Int J Fertil Steril. 2024;18:293.","journal-title":"Int J Fertil Steril"},{"key":"1789_CR24","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1016\/S1472-6483(10)61779-8","volume":"9","author":"A Agarwal","year":"2004","unstructured":"Agarwal A, Said TM. Implications of systemic malignancies on human fertility. Reprod Biomed Online. 2004;9:673\u20139.","journal-title":"Reprod Biomed Online"},{"key":"1789_CR25","first-page":"568","volume":"32","author":"MM Quinn","year":"2017","unstructured":"Quinn MM, et al. Response to ovarian stimulation is not impacted by a breast cancer diagnosis. Hum Reprod. 2017;32:568\u201374.","journal-title":"Hum Reprod"},{"key":"1789_CR26","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1016\/j.rbmo.2018.01.016","volume":"36","author":"C Decanter","year":"2018","unstructured":"Decanter C, et al. Prospective assessment of follicular growth and the oocyte cohort after ovarian stimulation for fertility preservation in 90 cancer patients versus 180 matched controls. Reprod Biomed Online. 2018;36:543\u201351.","journal-title":"Reprod Biomed Online"},{"key":"1789_CR27","doi-asserted-by":"publisher","first-page":"1476","DOI":"10.1016\/j.fertnstert.2013.03.029","volume":"99","author":"H Cakmak","year":"2013","unstructured":"Cakmak H, Rosen MP. Ovarian stimulation in cancer patients. Fertil Steril. 2013;99:1476\u201384.","journal-title":"Fertil Steril"},{"key":"1789_CR28","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1016\/j.fertnstert.2008.10.007","volume":"93","author":"RB Quintero","year":"2010","unstructured":"Quintero RB, et al. Ovarian stimulation for fertility preservation in patients with cancer. Fertil Steril. 2010;93:865\u20138.","journal-title":"Fertil Steril"},{"key":"1789_CR29","first-page":"2051","volume":"33","author":"R Alvarez","year":"2018","unstructured":"Alvarez R, Ramanathan P. Fertility preservation in female oncology patients: the influence of the type of cancer on ovarian stimulation response. Hum Reprod. 2018;33:2051\u20139.","journal-title":"Hum Reprod"},{"key":"1789_CR30","doi-asserted-by":"publisher","first-page":"1621","DOI":"10.1016\/j.fertnstert.2010.12.041","volume":"95","author":"A Moria","year":"2011","unstructured":"Moria A, et al. Ovarian reserve and oocyte maturity in women with malignancy undergoing in vitro maturation treatment. Fertil Steril. 2011;95:1621\u20133.","journal-title":"Fertil Steril"},{"key":"1789_CR31","doi-asserted-by":"publisher","first-page":"504","DOI":"10.3332\/ecancer.2015.504","volume":"9","author":"E Mu\u00f1oz","year":"2015","unstructured":"Mu\u00f1oz E, et al. Ovarian stimulation in patients with breast cancer. Ecancermedicalscience. 2015;9:504.","journal-title":"Ecancermedicalscience"},{"key":"1789_CR32","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1016\/j.rbmo.2012.02.020","volume":"24","author":"MAC Vizca\u00edno","year":"2012","unstructured":"Vizca\u00edno MAC, et al. The effects of letrozole on ovarian stimulation for fertility preservation in cancer-affected women. Reprod Biomed Online. 2012;24:606\u201310.","journal-title":"Reprod Biomed Online"},{"key":"1789_CR33","doi-asserted-by":"crossref","unstructured":"Anderson RA, Wallace WHB. Antim\u00fcllerian hormone, the assessment of the ovarian reserve, and the reproductive outcome of the young patient with cancer. Fertil Steril. 2013; 99:1469\u201375.","DOI":"10.1016\/j.fertnstert.2013.03.014"},{"key":"1789_CR34","doi-asserted-by":"publisher","first-page":"102215","DOI":"10.1016\/j.jogoh.2021.102215","volume":"50","author":"R Cioffi","year":"2021","unstructured":"Cioffi R, et al. Do stage and grade of malignancy impact fertility preservation in breast cancer patients? J Gynecol Obstet Hum Reprod. 2021;50:102215.","journal-title":"J Gynecol Obstet Hum Reprod"},{"key":"1789_CR35","first-page":"1","volume":"18","author":"J Jones","year":"2012","unstructured":"Jones J, Mosher WD, Daniels K. Current contraceptive use in the united states, 2006\u20132010, and changes in patterns of use since 1995. Natl Health Stat Rep. 2012;18:1\u20135.","journal-title":"Natl Health Stat Rep"},{"key":"1789_CR36","doi-asserted-by":"publisher","first-page":"2364","DOI":"10.1093\/humrep\/dev197","volume":"30","author":"K Birch Petersen","year":"2015","unstructured":"Birch Petersen K, et al. Ovarian reserve assessment in users of oral contraception seeking fertility advice on their reproductive lifespan. Hum Reprod. 2015;30:2364\u201375.","journal-title":"Hum Reprod"},{"key":"1789_CR37","doi-asserted-by":"publisher","first-page":"993","DOI":"10.3109\/09513590.2013.819083","volume":"29","author":"A Revelli","year":"2013","unstructured":"Revelli A, et al. Is letrozole needed for controlled ovarian stimulation in patients with Estrogen receptor-positive breast cancer? Gynecol Endocrinol. 2013;29:993\u20136.","journal-title":"Gynecol Endocrinol"},{"key":"1789_CR38","doi-asserted-by":"publisher","first-page":"4347","DOI":"10.1200\/JCO.2005.05.037","volume":"23","author":"K Oktay","year":"2005","unstructured":"Oktay K, et al. Fertility preservation in breast cancer patients: a prospective controlled comparison of ovarian stimulation with Tamoxifen and letrozole for embryo cryopreservation. J Clin Oncol. 2005;23:4347\u201353.","journal-title":"J Clin Oncol"},{"key":"1789_CR39","doi-asserted-by":"publisher","first-page":"2630","DOI":"10.1200\/JCO.2007.14.8700","volume":"26","author":"AA Azim","year":"2008","unstructured":"Azim AA, Costantini-Ferrando M, Oktay K. Safety of fertility preservation by ovarian stimulation with letrozole and gonadotropins in patients with breast cancer: a prospective controlled study. J Clin Oncol. 2008;26:2630\u20135.","journal-title":"J Clin Oncol"},{"key":"1789_CR40","doi-asserted-by":"publisher","first-page":"574669","DOI":"10.3389\/fonc.2020.574669","volume":"10","author":"B Bonardi","year":"2020","unstructured":"Bonardi B, et al. Efficacy and safety of controlled ovarian stimulation with or without letrozole co-administration for fertility preservation: A systematic review and meta-analysis. Front Oncol. 2020;10:574669.","journal-title":"Front Oncol"},{"key":"1789_CR41","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1093\/humrep\/deac035","volume":"37","author":"L Arecco","year":"2022","unstructured":"Arecco L, et al. Safety of fertility preservation techniques before and after anticancer treatments in young women with breast cancer: a systematic review and meta-analysis. Hum Reprod. 2022;37:954\u201368.","journal-title":"Hum Reprod"},{"key":"1789_CR42","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1002\/mrd.10107","volume":"61","author":"Y Hu","year":"2002","unstructured":"Hu Y, et al. Effects of aromatase Inhibition on in vitro follicle and oocyte development analyzed by early preantral mouse follicle culture. Mol Reprod Dev. 2002;61:549\u201359.","journal-title":"Mol Reprod Dev"},{"key":"1789_CR43","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1016\/j.fertnstert.2012.06.007","volume":"98","author":"B Almog","year":"2012","unstructured":"Almog B, et al. Effects of cancer on ovarian response in controlled ovarian stimulation for fertility preservation. Fertil Steril. 2012;98:957\u201360.","journal-title":"Fertil Steril"},{"key":"1789_CR44","doi-asserted-by":"publisher","first-page":"1994","DOI":"10.1016\/j.fertnstert.2013.02.004","volume":"99","author":"JA Garcia-Velasco","year":"2013","unstructured":"Garcia-Velasco JA, et al. Five years\u2019 experience using oocyte vitrification to preserve fertility for medical and nonmedical indications. Fertil Steril. 2013;99:1994\u20139.","journal-title":"Fertil Steril"}],"container-title":["Journal of Ovarian Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13048-025-01789-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13048-025-01789-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13048-025-01789-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T00:03:01Z","timestamp":1760486581000},"score":1,"resource":{"primary":{"URL":"https:\/\/ovarianresearch.biomedcentral.com\/articles\/10.1186\/s13048-025-01789-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,14]]},"references-count":44,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1789"],"URL":"https:\/\/doi.org\/10.1186\/s13048-025-01789-x","relation":{},"ISSN":["1757-2215"],"issn-type":[{"value":"1757-2215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,14]]},"assertion":[{"value":"3 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The ethical clearance was issued by the Royan Institute Ethics Committee (IR.ACECR.ROYAN.REC.1398.206), Tehran, Iran, in compliance with the Helsinki Declaration.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human ethics and consent to participate declarations"}}],"article-number":"222"}}